Addyi Geriatric (65+) Monitoring: What Clinicians and Patients Need to Know About Flibanserin in Older Women

What Is Flibanserin and Why Does Age Change the Risk Profile?

Flibanserin is a non-hormonal, centrally acting agent approved by the FDA in August 2015 for hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts as a serotonin 1A agonist and serotonin 2A antagonist, with secondary dopamine D4 agonism. Those receptor-level actions produce modest improvements in sexual desire but also CNS depression, dizziness, and syncope, side effects that scale sharply with age-related physiologic changes [1].

Women aged 65 and older experience predictable pharmacokinetic shifts. Hepatic blood flow declines roughly 40% between ages 25 and 75, slowing CYP3A4-mediated first-pass metabolism [2]. Glomerular filtration rate drops an average of 0.75 mL/min per year after age 40, altering renal clearance of flibanserin metabolites [3]. Body fat fraction rises while lean mass falls, expanding the volume of distribution for lipophilic drugs. Each change alone is manageable; together, they can turn a standard 100 mg bedtime dose into a functionally higher exposure than the label was designed around.

The FDA label does not include a geriatric-specific dose reduction, partly because the key trials enrolled almost exclusively premenopausal women. The BEGONIA trial (N=949, published J Sex Med 2014) reported a statistically significant increase in satisfying sexual events (SSEs) per 28 days versus placebo, but the trial population had a mean age of 36 years [4]. Applying that evidence to a 70-year-old requires clinical judgment that the trial data alone cannot fully support.

Prescribers should document the off-label nature of geriatric use in the chart and obtain informed consent that addresses the absence of age-specific trial data before initiating therapy [5].

FDA REMS Requirements and Their Specific Implications for Older Patients

The FDA's Risk Evaluation and Mitigation Strategy (REMS) for flibanserin mandates that prescribers complete a certified training module, that pharmacies be certified dispensers, and that patients acknowledge the alcohol prohibition in writing before each dispensing [1]. For geriatric patients, the alcohol restriction deserves extra weight.

Older adults metabolize ethanol more slowly due to reduced alcohol dehydrogenase activity and decreased total body water [6]. Even one drink that a 40-year-old clears in two hours may produce a blood alcohol level 30 to 50% higher in a 70-year-old of similar weight. Combined with flibanserin's CNS depressant properties, that pharmacokinetic difference substantially raises the risk of severe hypotension and loss of consciousness. The FDA required this warning after a dedicated drug-interaction study showed that concurrent alcohol use reduced standing systolic blood pressure by a mean of 27 mmHg [1].

Clinicians prescribing to patients 65 and older should ask about alcohol use at every visit using the AUDIT-C tool, not solely at enrollment [7]. A score of 3 or higher in women warrants a direct conversation about absolute contraindication before continuing the prescription.

REMS certification itself does not expire, but patient re-counseling should occur at each 90-day refill for geriatric patients given the higher risk of new alcohol-interactive medications appearing between visits [5].

Polypharmacy and CYP3A4 Drug Interactions in the Geriatric Population

Polypharmacy is the rule, not the exception, in patients over 65. Adults in this age group take a median of five prescription medications, and roughly 40% take eight or more [8]. Flibanserin's dependence on CYP3A4 for hepatic clearance makes that polypharmacy burden directly dangerous.

Moderate CYP3A4 inhibitors, including fluconazole, erythromycin, and grapefruit juice, can raise flibanserin area under the curve (AUC) by approximately 2-fold [1]. Strong inhibitors such as ketoconazole, clarithromycin, and ritonavir raise AUC up to 4.5-fold [1]. At those plasma concentrations, the incidence of syncope and severe hypotension rises to the point where the FDA lists strong CYP3A4 inhibitors as a contraindicated combination.

Common geriatric prescriptions that carry CYP3A4 inhibitory activity include:

• Fluconazole (antifungal, commonly prescribed for recurrent vulvovaginal candidiasis)
• Diltiazem and verapamil (calcium-channel blockers for hypertension or atrial fibrillation)
• Clarithromycin and erythromycin (antibiotics for respiratory or skin infections)
• Amiodarone (antiarrhythmic)
• Cimetidine (histamine-2 blocker, available OTC)

Clinicians should run a full medication reconciliation at every visit using a validated interaction checker. A single short-course clarithromycin prescription for a sinus infection in a patient who takes nightly flibanserin creates a meaningful syncope risk that neither the patient nor a non-prescribing clinician may recognize without explicit counseling [9].

CYP3A4 inducers such as rifampin, carbamazepine, and St. John's Wort reduce flibanserin exposure and may eliminate any therapeutic effect. Herbal supplement use, common in older women, should be screened at every visit [10].

Monitoring Renal and Hepatic Function in Patients 65 and Older

Flibanserin is primarily hepatically metabolized. The FDA label contraindicates its use in any patient with hepatic impairment, because even mild elevation of liver enzymes correlates with substantially increased flibanserin exposure [1]. For geriatric patients, the relevant concern is often subclinical hepatic change: fatty liver disease, age-related decline in hepatic perfusion, or low-grade drug-induced hepatic stress from concurrent medications such as statins or NSAIDs [2].

Baseline liver function tests (LFTs) including ALT, AST, and total bilirubin should be obtained before prescribing. If ALT or AST exceeds the upper limit of normal, flibanserin should not be started. Repeat LFTs every 6 months in patients 65 and older, even if baseline values are normal, given the higher background rate of hepatic change in this population [11].

Renal clearance of flibanserin metabolites, while secondary to hepatic metabolism, still requires attention. Estimated glomerular filtration rate (eGFR) should be documented at baseline and rechecked every 6 months. When eGFR falls below 30 mL/min/1.73 m², the prescriber should consult the label's limited renal-impairment guidance and consider deprescribing, because trial data do not cover that subgroup [3].

Creatinine alone is an unreliable marker in older women due to reduced muscle mass producing less creatinine despite meaningful nephron loss. The CKD-EPI equation, which accounts for age and sex, provides a more accurate eGFR estimate and should be used instead of relying on creatinine alone [12].

Falls, Orthostatic Hypotension, and CNS Depression: The Core Geriatric Safety Triad

Falls are the leading cause of injury-related death in adults over 65 in the United States, and the CDC estimates that one in four adults 65+ falls each year [13]. Flibanserin's most common adverse effects in clinical trials were dizziness (11.4%), somnolence (11.2%), and nausea (10.4%) [1]. Each of those effects contributes independently to fall risk, and their combination is additive.

Orthostatic hypotension deserves particular attention. Blood pressure should be measured supine and then standing (at 1 minute and 3 minutes after standing) at every visit for a geriatric patient on flibanserin. A systolic drop of 20 mmHg or more, or a diastolic drop of 10 mmHg or more, meets the consensus definition of orthostatic hypotension and warrants immediate dose reassessment [14].

Older women frequently take antihypertensive medications. Adding flibanserin to an ACE inhibitor, ARB, beta-blocker, or diuretic increases the likelihood of additive hypotensive effect. The combination with alpha-blockers such as tamsulosin (sometimes prescribed off-label for bladder dysfunction in older women) is especially risky and requires explicit monitoring [15].

Somnolence and dizziness from flibanserin peak within the first two hours after ingestion. Advising patients to take the dose at bedtime, in bed, reduces but does not eliminate fall risk. Nighttime bathroom trips remain a meaningful exposure window. Installing nightlights, using bedside commodes, and removing floor hazards are practical interventions that prescribers should recommend at initiation [13].

Cognitive status also matters. Mild cognitive impairment affects roughly 15 to 20% of adults over 65 [16]. Patients with MCI may have difficulty reliably adhering to the alcohol prohibition or recognizing early warning signs such as dizziness before a fall. A brief validated screen such as the Mini-Cog at baseline and annually helps identify patients who may not be able to safely self-monitor [16].

Cardiovascular Screening Before and During Flibanserin Therapy

Flibanserin does not carry a formal cardiac contraindication beyond the hypotension risk, but baseline cardiovascular assessment is prudent in any patient 65 and older. Resting blood pressure, heart rate, and a medication review for QT-prolonging agents should be documented before prescribing [17].

Flibanserin itself does not appear to prolong the QT interval at therapeutic doses, but clarithromycin and several other CYP3A4 inhibitors do. A patient who develops an arrhythmia requiring macrolide therapy while on flibanserin faces both an interaction and a concurrent QT concern [17]. Proactive documentation of a "sick-day" plan, specifying which medications require flibanserin to be held temporarily, reduces that risk.

Resting heart rate below 60 bpm (common in women on beta-blockers) combined with flibanserin's mild hypotensive tendency may produce symptomatic bradycardia. Heart rate should be checked at every monitoring visit [15].

Assessing Efficacy: When Flibanserin Is Not Working Well Enough to Justify Continued Use

The FDA label states that flibanserin should be discontinued if there is no improvement after 8 weeks at the full 100 mg dose [1]. That standard applies to all patients, but geriatric patients bear additional risk from continued exposure without commensurate benefit.

The BEGONIA trial (N=949) reported a mean increase of 0.5 additional SSEs per 28 days versus placebo at the primary endpoint [4]. That magnitude of benefit is real but modest. In a 70-year-old with a falls history, osteoporosis, or polypharmacy burden of 8 or more drugs, a benefit of 0.5 additional SSEs per month may not outweigh the cumulative risk exposure.

A structured benefit-risk reassessment at 8 weeks using the following criteria helps standardize that decision:

1. Patient-reported change in satisfying sexual events (target: at least 1 additional SSE per 28 days vs. baseline)
2. Patient Global Impression of Change score of "much improved" or "very much improved"
3. Absence of orthostatic hypotension on standing blood pressure measurement
4. No new CYP3A4 inhibitors added to the medication list since last visit
5. Confirmed alcohol abstinence on AUDIT-C re-screen (score 0-2)
6. eGFR stable or within 10% of baseline
7. No new falls or near-falls reported since initiation

If criteria 1 and 2 are not met at 8 weeks, deprescribing is clinically appropriate regardless of side-effect profile [5].

Deprescribing Flibanserin: A Practical Approach for Geriatric Patients

Deprescribing flibanserin does not require a taper. The drug has no known withdrawal syndrome, and abrupt discontinuation carries no pharmacologic risk [1]. The practical steps are:

First, the prescriber should confirm the indication remains valid. HSDD diagnosis in older women should be reassessed annually. Relationship changes, grief, depression, and androgen status all affect sexual desire independently of the drug, and some patients may have experienced natural desire recovery [18].

Second, the patient should be counseled that stopping flibanserin will not cause withdrawal symptoms. Many patients assume any nightly medication requires tapering. Clearing that misconception reduces unnecessary continued use.

Third, if a patient has been taking flibanserin for more than 12 months without a formal benefit-risk reassessment, that reassessment should happen before the next renewal. Studies of medication adherence in older adults show that roughly 30% of long-term prescriptions in patients over 65 continue without a documented indication review within the prior year [19].

Finally, consider whether the underlying HSDD has a treatable contributing cause. Depression screening with the PHQ-9, thyroid function testing, and review of libido-suppressing medications (beta-blockers, SSRIs, antiandrogens) may identify reversible factors that make flibanserin unnecessary [18].

Counseling Geriatric Patients and Their Caregivers

Clear communication at initiation reduces adverse events. The following points should be covered at the first prescribing visit and reinforced at every refill:

Absolute alcohol prohibition means zero alcohol, not reduced alcohol. The FDA REMS acknowledgment form should be re-signed annually or whenever the patient transitions to a new pharmacy [1].

Dizziness is most likely in the first two weeks. Patients should not drive or operate machinery within 6 hours of taking the dose. Because flibanserin is taken at bedtime, morning driving after an 8-hour sleep window typically carries acceptable residual sedation, but individual variation in CYP3A4 activity means some women may have longer half-lives [20].

Family members or caregivers should know the drug name and its alcohol interaction. In the event of suspected hypotension or syncope, they should call 911 and inform emergency personnel of both the drug and any recent alcohol exposure. Medical alert jewelry or a medication card in the patient's wallet is a practical safeguard.

Sexual health is a legitimate health concern at any age. The American College of Obstetricians and Gynecologists affirms that older women's sexual health deserves the same clinical attention as other aspects of well-being, and prescribers should communicate that this monitoring plan exists to make therapy as safe as possible, not to discourage its use [21].

Suggested Monitoring Schedule for Flibanserin in Patients 65 and Older

The following schedule synthesizes FDA label requirements, pharmacokinetic considerations, geriatric pharmacology principles, and published geriatric prescribing guidelines [5, 11, 15]:

Before starting:

• Confirm HSDD diagnosis with validated instrument (DSDS or FSFI)
• Obtain baseline LFTs (ALT, AST, total bilirubin), eGFR (CKD-EPI), and orthostatic blood pressure
• Run full medication reconciliation for CYP3A4 inhibitors and inducers
• Screen for alcohol use (AUDIT-C)
• Complete REMS prescriber certification and patient acknowledgment form
• Document off-label use and obtain written informed consent

At 4 weeks:

• Orthostatic blood pressure and resting heart rate
• Falls screen (any falls or near-falls since initiation)
• Alcohol use re-screen
• Medication reconciliation for new CYP3A4 inhibitors
• Patient-reported SSE count vs. baseline

At 8 weeks:

• Full benefit-risk reassessment using the 7-criterion framework above
• Repeat LFTs if any new hepatotoxic medication added
• Decision: continue, dose-hold, or discontinue

Every 6 months (ongoing):

• Repeat LFTs, eGFR
• Orthostatic blood pressure
• AUDIT-C alcohol screen
• Medication reconciliation
• Annual REMS patient acknowledgment renewal
• Annual HSDD indication reassessment

Immediately if any of the following occur:

• Fall or syncope episode
• New CYP3A4 inhibitor prescribed
• LFT elevation above upper limit of normal
• eGFR drop below 30 mL/min/1.73 m²
• Patient reports any alcohol use